10
10 patent holders with MPP signed agreements
26
26 million patient-years through MPP’s generic partners from January 2012 to June 2019
23
23 generic manufacturers and product developers sublicensed from the MPP
18
18 products licensed to the MPP
150+
150+ ongoing pharmaceutical development projects
87% to 91%
87% to 91% of people living with HIV in developing countries covered by the MPP adult licences
92 to 131
92 to 131 countries covered by MPP adults licences
1.23
1.23 billion dollars saved, from January 2012 to June 2019